Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

Oracle Shares Surge on Unprecedented $455 Billion Contract Backlog

Dieter Jaworski by Dieter Jaworski
September 10, 2025
in Earnings, Mergers & Acquisitions, Nasdaq, Tech & Software
0
Oracle Stock
0
SHARES
151
VIEWS
Share on FacebookShare on Twitter

A staggering $455 billion in committed future business sent Oracle Corporation’s stock soaring, with shares rocketing approximately 27% in extended trading. The software behemoth demonstrated its rapidly expanding influence in the competitive cloud computing sector, overshadowing a quarterly performance that narrowly missed certain analyst forecasts.

Unmatched Visibility Fuels Investor Confidence

While Oracle’s earnings per share of $1.47 came in slightly below the anticipated $1.48, the monumental scale of its contracted future revenue captivated the market. The company’s Remaining Performance Obligations (RPO), a key metric of booked but unrecognized revenue, skyrocketed by an astonishing 359% year-over-year. CEO Safra Catz attributed this surge to “four multi-billion-dollar contracts secured with three distinct customers.”

This colossal backlog provides Oracle with exceptional financial predictability. A significant portion of the revenue outlined in its ambitious five-year forecast is already contractually secured. Management anticipates its RPO will surpass the half-trillion-dollar threshold within the coming months.

Aggressive Growth Trajectory Targets Cloud Leaders

Oracle unveiled a bold expansion plan squarely aimed at the industry’s dominant forces. The company issued specific revenue projections for its cloud infrastructure division:

  • Fiscal 2026: $18 billion (representing 77% growth)
  • Fiscal 2027: $32 billion
  • Fiscal 2028: $73 billion
  • Fiscal 2029: $114 billion
  • Fiscal 2030: $144 billion

This projected growth trajectory would position Oracle’s cloud business within striking distance of Amazon Web Services ($112 billion in annual revenue) and Microsoft Azure ($75 billion). Chairman Larry Ellison highlighted the company’s momentum, noting, “MultiCloud database revenue from Amazon, Google, and Microsoft grew an incredible 1,529% this quarter.”

Should investors sell immediately? Or is it worth buying Oracle?

Strategic AI Alliances Accelerate Market Position

Oracle is capitalizing on the artificial intelligence revolution through key partnerships. Google’s Gemini AI models will become available on Oracle Cloud Infrastructure, while a separate capacity agreement for 4.5 gigawatts with OpenAI significantly deepens their collaboration.

Further strengthening its AI offerings, the company will launch the “Oracle AI Database Service” in October. This new service will enable clients to run AI models directly on their existing Oracle databases. Ellison emphasized the shift in customer engagement, stating, “Historically, we didn’t negotiate with CEOs. Now we’re doing exactly that.”

Solid Operational Performance Amidst Revenue Shortfall

Despite reporting revenue of $14.93 billion, which fell short of the $15.04 billion consensus estimate, Oracle displayed robust operational health:

  • Total Cloud Revenue: $7.2 billion (a 28% increase)
  • Cloud Infrastructure Revenue: $3.3 billion (a 55% jump)
  • Operating Income: $6.2 billion (up 9%)
  • Operating Cash Flow: $21.5 billion (a 13% rise)

The company plans to increase capital expenditures to $35 billion by 2026. CEO Catz characterized this spending plan as a “comparatively asset-light” strategy when measured against the investments required by competitors.

Oracle is successfully executing a remarkable transformation, evolving from a established software giant into a formidable cloud and AI contender—with the signed contracts to validate its strategic direction.

Ad

Oracle Stock: Buy or Sell?! New Oracle Analysis from February 8 delivers the answer:

The latest Oracle figures speak for themselves: Urgent action needed for Oracle investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Oracle: Buy or sell? Read more here...

Tags: Oracle
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock
Healthcare

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Next Post
Walgreens Stock

Walgreens Concludes Public Trading Era with Landmark Private Equity Acquisition

Eos Energy Enterprises Stock

Eos Energy Enterprises: A Tale of Technological Promise and Financial Reality

Arcellx Stock

Arcellx Stock Analysis: Assessing the Biotech's Market Position

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com